Abstract 1579P
Background
The US Surveillance, Epidemiology, and End Result (SEER) data indicated an increasing incidence of early-onset GI tract cancers. According to published data, the treatment outcomes of young adults (YA) are comparable to the general population. We aimed to analyze the clinicopathological characteristics and overall survival (OS) of YA treated in a comprehensive cancer center.
Methods
Patients diagnosed with oesophagal (OC), oesophagogastric junction (OGJ), or gastric (GC) cancer between 2010 and 2022 were retrospectively identified from the Masaryk Memorial Cancer Institute database. Inclusion criteria were 1) age 18-50 years, 2) histology, and 3) treatment according to international recommendations.
Results
The consecutive patient cohort included 1725 patients, of which 162 met the inclusion criteria, representing approximately 10% of YA patients from the Czech Republic. In 63% of cases, the patients were men, significantly older than women (84% vs 65% in the age group 40-49 years, p=0.005). In women, tumors were more often located in the stomach (78% vs 53%, p=0.001) and primary metastatic (67% vs 50%, p=0.039). Six patients had localized disease (stage I), 36 (16 OC/OGJ, 20 GC) underwent radical resection, 31 (15 OC/OGJ, 16 GC) were unresectable, and 86 metastatic (25 OC/OGJ, 61 GC). With a median follow-up of 67 months, 131 (81%) deaths were recorded. Radically resected patients achieved a median OS of 54 mo with a 5-year OS of 42%, whereas the median OS for the unresectable and metastatic disease was 11 mo, and 8.6 mo, respectively.
Conclusions
In our YA cohort, men were older, while women were more likely to have metastatic gastric cancer. OS for the locally advanced disease was comparable to published studies observing the general population but noticeably shorter for metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22